



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: July 31, 2009

To: N083E Investigators, CRAs, and Study Teams

From: Lynn M Flickinger
NCCTG Project Manager

Re: N083E, Phase II Safety Study of Docetaxel and Carboplatin in Combination with Trastuzumab and Lapatinib in Early Breast Cancer

End of Safety Teleconferences for Investigators Entering Patients in the Safety Cohort

Per protocol, the investigators who enter patients into the Safety Cohort were required to participate in twice-monthly teleconferences to discuss adverse events and issues related to patient safety. These calls are to facilitate rapid sharing of information regarding patient safety for this drug combination.

The evaluation of first cycle data from the first 10 patients enrolled is now complete. The teleconferences scheduled on 2nd and 4th Thursdays of each month are canceled as of 7/30/2009.

If you have any questions about the information in this memo, please email Lynn Flickinger at flickinger.lynn@mayo.edu or Kristen Perkins at perkins.kristen@mayo.edu.